A Phase1 Study, to Determine the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of Single and Multiple Doses of Orally Administered HM71224 in Healthy, Adult Male Volunteers
Phase of Trial: Phase I
Latest Information Update: 13 Jun 2015
Price : $35 *
At a glance
- Drugs Poseltinib (Primary)
- Indications Rheumatoid arthritis
- Focus Adverse reactions; First in man
- Sponsors Hanmi Pharmaceutical
- 13 Jun 2015 Results presented at the 16th Annual Congress of the European League Against Rheumatism.
- 17 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 17 Jun 2014 According to a Hanmi Pharmaceuticals media release, interim results of this trial were presented at the Annual Congress of the European League Against Rheumatism.